In part 3, the conclusion of this Exclusive Interview, Grenye O’Malley talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about the unique aspects of a new trial that studies the artificial pancreas and the benefits for people on multiple daily injections who may not want to use a pump.
Grenye O’Malley, MD is an endocrinology fellow at Mount Sinai in New York.
Transcript of this video segment:
Freed: It also says that you’re participating in a large multiple trial for the artificial pancreas and it says it’s a first of its kind. What makes it the first of its kind?
O’Malley: I am involved in two trials with the in-control group, which is out of the University of Virginia and one is in a hybrid closed group trial that is using pumps. Then there’s another trial that is the first of its kind which tries to take the technology and the algorithms and all the benefits of artificial pancreas but apply it in a way that benefits people who are using multiple daily injections. So, it is a system where the algorithm can actually talk to the insulin pens and see how much insulin is on board so that they can then make suggestions for how to adjust doses, work with the CGM data to try to predict lows and highs, and give more of that information and more of those benefits to people who may not want to use a pump.
Freed: So, in your study, is it a true closed system or do you still have to use the carb ratios?
O’Malley: In that trial, it’s a hybrid system so they’re still using your own carbohydrate ratios. I think in the future, one of the things that I think from this poster is that since in pregnant women their biggest changes are in carbohydrate ratios and ideal artificial pancreas system in them, would have some sort of way to automatically adjust carbohydrate ratios.
Freed: And what’s the future for studies with the artificial pump?
O’Malley: So, what we hope to do with this data is have enough as well as collect more data on pregnant women to see what happens in pregnant women who are well controlled and do this in order to develop algorithms for an artificial pancreas in pregnancy. And I think this would not only be really helpful for pregnant women who have such strict controls and have such high risk of hypoglycemia, but also it would be a proof of concept that we can get to tight goals. If we can get pregnant women down to 90 or below 90 in the morning, then that means that it is good for the entire field and that, that’s possible. And then also having something that can actually change with predictions of what week in pregnancy – that will also benefit women who have menstrual cycles that need different adjustments – something that can actually adjust or at least predict changes in anyone.
Freed: Well, I want to thank you for your time, I thought it was very interesting and enjoy the rest of your stay here.
O’Malley: Thank you, I will.